Archive 2017 2017 - 01 Dec 2017 – China Medical System Holdings Limited invests £3.0 million in Destiny Pharma - 01 Dec 2017 – Regional development and commercialisation agreement finalised with China Medical System Holdings Limited - 30 Oct 2017 – MRSA superbug spreading from hospitals across UK - 09 Oct 2017 – United Nations group to meet in Berlin in October 2017 to discuss global issue of Anti-Microbial Resistance - 27 Sep 2017 – Destiny Pharma to push ahead with next-generation antibiotic after £15 million IPO - 27 Sep 2017 – Destiny Pharma announce interim results 27th September 2017 - 19 Sep 2017 – More support announced for new antibiotics - 04 Sep 2017 – Framework Agreement with China Medical Systems - 04 Sep 2017 – Admission and First Day of Dealings on AIM - 01 Sep 2017 – Destiny Pharma plc publishes Supplementary AIM Admission Document - 29 Aug 2017 – Destiny Pharma plc publishes AIM Admission Document - 18 Aug 2017 – Notification of Intention to Admit Shares to Trading on the Alternative Investment Market of the London Stock Exchange - 13 Jul 2017 – G20 Declaration on Combatting Antimicrobial Resistance (AMR) 7-8th July 2017 - 07 Jul 2017 – To the G20: Incentivise Antibacterial Drug R&D - 07 Jul 2017 – Destiny’s Brainchild (South East Business Magazine) - 14 Jun 2017 – Regulators from EU, U.S. and Japan join forces on antimicrobial trials - Destiny Pharma in attendance at the 18th Bio€quity Europe Meeting, Paris, France - 09 May 2017 – Destiny Board Member Elected to the Academy of Medical Sciences - 13 Apr 2017 – Destiny Pharma announces appointment of new CEO - Destiny Pharma to attend the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria - Destiny Pharma to attend Bio-Europe Meeting, Barcelona, Spain - Destiny Pharma to present at the 18th BioEquity Europe Meeting, Paris, France Archive 2019 2018 2017 2016 2015
